Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?
about
Hepatitis C in Liver Allograft Recipients: Utility of One-Year Post-Transplantation Biopsy as an Indicator of Antiviral TherapyThe accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4.Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply.
P2860
Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Editorial: can we afford the n ...... ent of genotype 1 hepatitis C?
@en
Editorial: can we afford the n ...... ent of genotype 1 hepatitis C?
@nl
type
label
Editorial: can we afford the n ...... ent of genotype 1 hepatitis C?
@en
Editorial: can we afford the n ...... ent of genotype 1 hepatitis C?
@nl
prefLabel
Editorial: can we afford the n ...... ent of genotype 1 hepatitis C?
@en
Editorial: can we afford the n ...... ent of genotype 1 hepatitis C?
@nl
P2860
P356
P1476
Editorial: can we afford the n ...... ent of genotype 1 hepatitis C?
@en
P2093
P2860
P304
P356
10.1111/APT.12927
P407
P577
2014-10-01T00:00:00Z